Metraipolis › archive › dc_de2beb416a3e

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in… — Europe PMC PMID:41008911

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41008911
DOI
10.3390/cancers17183070
License (as archived)
solo-consultazione
Archived
2026-11-09T21:05:50.860Z
SHA-256 of the archived text
d722f5ff38a0764172af6b8ce1fa1838c82e2f05311c2ea872aff62ab0185de9
Stable URL of this page
https://metraipolis.com/documento/dc_de2beb416a3e

How to cite

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in… — Europe PMC PMID:41008911 — Europe PMC (en), https://europepmc.org/article/MED/41008911 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_de2beb416a3e (Metraipolis archive dc_de2beb416a3e, sha256 d722f5ff38a0764172af6b8ce1fa1838c82e2f05311c2ea872aff62ab0185de9)
BibTeX
@misc{dcde2beb416a3e,
  title = {Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in… — Europe PMC PMID:41008911},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41008911},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_de2beb416a3e; sha256 d722f5ff38a0764172af6b8ce1fa1838c82e2f05311c2ea872aff62ab0185de9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41008911. Agents can read the archived copy with the MCP tool read_document.